1	Changes in vaginal <i>Ureaplasma</i> and <i>Lactobacillus</i> due to antibiotic regimen for
2	premature rupture of membranes
3	
4	Short title: Changes in vaginal <i>Ureaplasma</i> and <i>Lactobacillus</i> due to antibiotic regimen
5	
6	
7	Authors
8	Haruna Kawaguchi ^{1,2} ¶ *, Yukiko Nakura ^{2&} , Ryo Yamamoto ¹ ,Shusaku Hayashi ¹ ,
9	Makoto Takeuchi ³ , Keisuke Ishii ¹ , Itaru Yanagihara ² ¶
10	1) Department of Maternal Fetal Medicine, Osaka Women's and Children's Hospital,
11	Osaka, Japan
12	2) Department of Developmental Medicine, Research Institute, Osaka Women's and
13	Children's Hospital, Osaka, Japan
14	3) Department of Pathology, Osaka Women's and Children's Hospital, Osaka, Japan
15	
16	*Correspondence author
17	E-mail: haruna@wch.opho.jp
18	¶ These authors contributed equally to this work.
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 &These authors also contributed equally to this work.

20

Abstract

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

Preterm premature rupture of membranes (PPROM) is associated with preterm delivery and neonatal complications. PPROM is often complicated by intra-amniotic inflammation and/or microbial invasion of the amniotic cavity with *Ureaplasma* or *Mycoplasma*. Various prophylactic antibiotic therapies have been proposed to prolong latency between PPROM and delivery, reduce the risk of clinical chorioamnionitis, and improve neonatal complications. However, information on the potential of azithromycin administration to reduce the microbial load of vaginal *Ureaplasma* and *Mycoplasma* remains lacking. This prospective cohort study included singleton pregnancies managed with prophylactic antibiotics for PPROM at less than 36 weeks of gestation. All patients received the standard antibiotic regimen for PPROM, which consisted of a single oral azithromycin and intravenous ampicillin every for 2 days followed by 5 days of oral amoxicillin. Vaginal swabs samples were collected when PPROM was confirmed and after the antibiotic regimen administration. The main outcome measures were to investigate the changes in vaginal *Ureaplasma*, *Mycoplasma*, and *Lactobacillus spp.* due to the antibiotic regimen. In addition, the association between the presence and changes in vaginal Ureaplasma and Mycoplasma, pregnancy outcomes, and neonatal complications were examined. Out of 82 eligible PPROM, 51 had positive vaginal *Ureaplasma*. Thirty-six

40 patients (52.2%) completed the antibiotic regimen. Among those with positive vaginal Ureaplasma who completed the antibiotic regimen, 75% experienced an increase in 42 vaginal *Ureaplasma* levels. For those who delivered before completing all antibiotic doses, 40% had increased vaginal *Ureaplasma* levels. Furthermore, the antibiotic regimen 43 44 resulted in decreased Lactobacillus spp. in almost all cases. However, vaginal 45 Ureaplasma changes were not found to be associated with neonatal sepsis or 46 bronchopulmonary dysplasia. This suggests that Ureaplasma became resistant to 47 azithromycin. Future studies are needed to revalidate current antibiotic therapy for 48 PPROM. 49 50 Keywords: Azithromycin, bronchopulmonary dysplasia, funisitis, histological chorioamnionitis, neonatal infection

41

51

Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Preterm premature rupture of membranes (PPROM) occurs in 2%–3% of pregnancies and is associated with preterm delivery, neonatal complications, and maternal sepsis.(1-4) PPROM is often complicated by intra-amniotic inflammation and/or microbial invasion of the amniotic cavity with *Ureaplasma* or *Mycoplasma*. (5) Both are linked to neonatal infections and chronic lung disease. (6) Various prophylactic antibiotic regimens were proposed to prolong the latency between PPROM and delivery, reduce the risk of clinical chorioamnionitis, and improve neonatal outcomes. (7-10) The American College of Obstetricians and Gynecologists recommends using erythromycin and ampicillin, but a regimen with azithromycin has been suggested as an alternative to erythromycin. (8, 11, 12) At our institution, patients with PPROM receive a standard antibiotic regimen consisting of a single oral dose of azithromycin and intravenous ampicillin for 2 days followed by 5 days of oral amoxicillin. However, it is unclear whether administering azithromycin can reduce the microbial load of vaginal *Ureaplasma* and *Mycoplasma* DNA. Therefore, this study aimed to investigate the changes in vaginal *Ureaplasma*, Mycoplasma, and Lactobacillus, as well as maternal blood Ureaplasma, resulting from the antibiotic regimen used for PPROM cases. In addition, the association between the

- 71 presence and changes in vaginal *Ureaplasma* and *Mycoplasma*, pregnancy outcomes,
- and neonatal complications were examined, and that aim was achieved.

Materials and Methods

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

This single-center, prospective cohort study included singleton pregnancies managed with prophylactic antibiotics for PPROM at less than 36 weeks of gestation between October 2019 and December 2021. Patients under the age of 20, those who received other antibiotics within 2 weeks of PPROM, and those allergic to ampicillin and azithromycin were excluded. All relevant national regulations and institutional policies were compiled, and the study was conducted under the tenets of the Helsinki Declaration. It was approved by the ethical review board of Osaka Women's and Children's Hospital (approval number, 1211; date of approval, June 3, 2019). Written informed consent was obtained from all study subjects. Recruitment of subjects for this study began on October 1, 2019 and ended on December 31, 2021. The standard deviation of the amount of vaginal *Ureaplasma* colonization was 10^{2.7}. To have a 90% power to detect changes above 10² colony-forming units/mL, the study aimed to enroll 80 patients. The perinatal management protocol for PPROM at our institution is as follows. The diagnosis of PPROM is confirmed by observing amniotic fluid leakage from the cervix or pooling in the vagina, along with positive diagnostic tests measuring vaginal pH. In cases where the diagnosis is not clearly confirmed, an immunochromatographic

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

strip test with insulin-like growth factor-binding protein-1 (ActimProma^R) is used to detect amniotic fluid in the vagina or ultrasound evaluation is used to confirm the presence of oligohydramnios. All patients were admitted to the hospital and received the standard antibiotic regimen for PPROM before 36 weeks of gestation with intravenous ampicillin (2 g dose every 6 hours) for 48 hours and single oral azithromycin (1 g dose) followed by oral amoxicillin (500 mg dose every 8 hours) for 5 days. Betamethasone was administrated for patients with gestational age less than 34 weeks and imminent delivery. Intravenous magnesium sulfate and/or ritodrine hydrochloride and/or oral nifedipine as tocolytic agents were administered when patients have short cervical length and frequent uterine contraction. Indications for delivery included clinical chorioamnionitis, onset of labor, nonreassuring fetal status, or gestational age beyond 36 weeks. Clinical chorioamnionitis was diagnosed based on the presence of maternal fever (≥38.0°C) and two or more clinical signs: maternal leukocytosis (white blood cell count >15,000/mm³), maternal tachycardia (heart rate > 100 beats/min), fetal tachycardia (heart rate > 160 beats/min), uterine tenderness, and purulent or foulsmelling amniotic fluid or vaginal discharge. (13) Vaginal swabs and maternal blood samples were collected from women when the diagnosis of PPROM was confirmed. The quantity of vaginal secretions was

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

measured by weighing the swab tube before and after the collection. Vaginal swabs were taken from the lateral vaginal walls and the anterior and posterior fornix, and they were transferred to a cobas® polymerase chain reaction (PCR) Media Dual Swab Sample Kit from Roche Diagnostics GmbH, Germany. Vaginal swabs and maternal blood samples were retaken after the completion of the antibiotic regimen. Scrapings of the placental surface were also performed. If delivery occurred before the completion of the regimen, vaginal swabs and maternal blood samples were collected before the delivery. These results were not available to managing clinicians. The amount and species of *Ureaplasma* collected from the vaginal secretions, along with the amount of Lactobacillus spp. and Mycoplasma (M.) hominis and the presence of inerolysin (poreforming toxin produced by Lactobacillus (L.) iners that can cause preterm labor) were determined using real-time PCR. The amount of *Ureaplasma* was also measured from maternal blood and placental surface. An increase or decrease of 10² or more in DNA copy numbers was considered significant. This study investigated neonatal and infant mortality and any of the following adverse perinatal outcomes for up to 6 months of age: neonatal intensive care unit admission, mechanical ventilation, respiratory distress syndrome, retinopathy of prematurity, intraventricular hemorrhage 3 or 4 grade, periventricular leukomalacia,

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

necrotizing enterocolitis, neonatal sepsis, bronchopulmonary dysplasia (BPD), and congenital anomaly. BPD is a chronic lung disease, which is most commonly seen in premature infants requiring respiratory support, including oxygen supplementation at 36 weeks corrected gestational age. (14) Neonatal sepsis is defined as the presence of a positive blood culture. (15) In this study, changes in vaginal *Ureaplasma*, *Mycoplasma*, and *Lactobacillus* are divided into two groups: complete and incomplete antibiotic protocols. Cases of complete protocol are defined as cases in which all antibiotic regimens had been completed. Cases of incomplete protocol are those who delivered in the middle of their antibiotic regimen, but all of them had received at least one intravenous ampicillin and oral azithromycin administration. DNA extraction and quantitative real-time PCR of *Ureaplasma* DNA was extracted from vaginal swab and maternal blood samples using a Maxwell® RSC Blood DNA Kit (AS1400, Promega, Japan). The DNA copy number of Ureaplasma was measured using QuantStudio 5Real-Time PCR System (Thermo Fisher Scientific) targeted for the 16S ribosomal RNA gene. The amplification reaction mixtures comprised 5 mL of TaqMan Fast Advanced Master Mix (Thermo Fisher

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

Scientific), primers (0.9 µM each), probe (Thermo Fisher Scientific, 0.25 µM), and 1 µL of DNA sample; this was adjusted to 10 µL with DDW. The primers and probe used were as follows: 16S-Urea F1(AGGCATGCGTCTAGGGTAGGA), 16S-Urea R1(ACGTTCTCGTAGGGATACCTTGTTA), and 16S-Urea-FAM-MGB probe (FAM-CGGTGACTGGAGTTAA-MGB). The PCR conditions were as follows: predenaturation at 95°C for 20 s, 40 cycles of denaturation at 95°C for 1 s, and annealing at 58 C for 20 s. The standard curve of *Ureaplasma* was determined using serial dilutions with copy numbers of 1.0×10^1 to 1.0×10^6 copies per reaction mixture by real-time PCR. In each run with clinical specimens, negative control and standards were included. To differentiate *Ureaplasma* (*U.*) parvum from *U. urealyticum*, the following primers and probes were used: ureG F2(CAACATTTAGTCCAGATTTAG), ureG R2(TAGCACCAACATAAGGAG), Up-FAM-MGB probe (FAM-TTGACCACCCTTACGAG-MGB), and Uu-VIC-MGB probe (VIC-TTGTCCGCCTTTACGAG-MGB). The amplification reaction mixtures comprised 5 mL of TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific), primers (0.9 µM each), probes (Thermo Fisher Scientific, 0.2 µM each), and 1 µL of sample DNA; this was adjusted to 10 µL with DDW.

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

12

(Thermo Fisher Scientific), and 1.0 µL of genomic DNA. PCR amplification was

performed under the following conditions: initial cycle of 95°C for 2 min, 35 cycles of 95°C for 1 s, 58°C for 15 s, and 72°C for 60 s.

2.4 Statistical analysis

Categorical and continuous variables were analyzed using chi-square or Fisher's exact tests and compared using Kruskal–Wallis test. Multivariate logistic regression analyses were performed to examine the adjusted odds ratios (aOR) and 95% confidence intervals (CI) for changes in *Ureaplasma* and perinatal outcomes. Statistical significance was set at P <0.05. Two-sided P-values were reported, and analyses were conducted using a JMP software (version 14; SAS Institute, Cary, NC, USA).

Results

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

In total, 82 patients with PPROM were included, and 51 were positive for vaginal *Ureaplasma*. Thirty-six patients (52.2%) completed the standard antibiotic regimen. (Figure 1) Of those who had positive vaginal *Ureaplasma* and completed the standard antibiotic regimen, vaginal *Ureaplasma* increased in 18 patients (75%). Among patients with positive vaginal *Ureaplasma* who delivered before the completion of all antibiotic doses, vaginal *Ureaplasma* increased in eight patients (40%). Fig 1. Flowchart of the study population. A total of 82 patients with PPROM were eligible for this study. Vaginal *Ureaplasma* was positive in 51 patients and negative in 31 patients. Of the patients who had positive vaginal *Ureaplasma* and completed the standard antibiotic regimen, 18 (75%) had increased vaginal *Ureaplasma* after treatment. Among patients with a positive vaginal Ureaplasma delivered before completion of all antibiotic doses, vaginal Ureaplasma increased in eight patients (40%). PPROM, preterm premature rupture of membranes; NEG, negative * intravenous 2 g ampicillin every 6 hours for 2 days, a single oral dose of 1 g

azithromycin, and 5 days of oral 500 mg amoxicillin every 8 hours.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

based on vaginal *Ureaplasma* changes by antibiotic treatment

227

		Ureaplasma	Ureaplasma (+		
		(-) at the time	of PPROM		
	Total	of PPROM	Decreased	Increased	p
			after	after	
			treatment	treatment	
	N = 69	N = 24	N = 18	N = 27	
maternal age at	33(23–46)	35 (26–46)	31.5 (22–41)	33 (23–42)	0.21
delivery					
nulliparous	40	10 (41.7)	14 (77.8)	16 (59.3)	0.06
history of	4	1 (4.2)	0	3 (11.1)	0.27
preterm birth					
Obesity (BMI	11	4 (16.7)	4 (22.2)	3 (11.1)	0.6
≧25)					
ART	10	3 (12.5)	2 (11.1)	5 (18.5)	0.74
tobacco use	4	1 (4.2)	1 (5.6)	2 (7.4)	0.88
during					
pregnancy					
СНТ	1	1 (4.2)	0	0	-
DM	0	0	0	0	-

	Ι_			T (() = 1	
history of	7	1 (4.2)	0	6 (22.2)	0.02
cervical					6
conization					
cerclage	6	2 (8.3)	2 (11.1)	2 (7.4)	0.91
antenatal	38	14 (58.3)	10 (55.6)	14 (51.9)	0.9
corticosteroid					
tocolysisa	39	13 (54.2)	10 (55.6)	16 (59.3)	0.93
HDP	4	2 (8.3)	0	2 (7.4)	0.47
GDM	7	1 (4.6)	3 (17.6)	3 (11.5)	0.42
antibiotics	69	24 (100)	18 (100)	27 (100)	-
complete	36	11 (45.8)	6 (33.3)	19 (70.4)	0.03
protocolb					8
azithromycin	69	24 (100)	18 (100)	27 (100)	-
GA at PPROM	31 + 6 (12 +	32 + 3 (20 + 0	32 + 2 (17 +	31 + 3 (12	0.43
	5~35 + 6)	\sim 35 + 6)	6~35+3)	+5~35+	
				2)	
GA at delivery	33 + 1 (17 +	33 + 2 (23 + 0	33 + 3 (18 +	32 + 4 (17	0.83
	5~36 + 4)	\sim 36 + 4)	1~36+1)	+5~36+	
				3)	
Latency ^c	7 (0–86)	5 (0–86)	3.5 (0–21)	10 (2–52)	0.01
					2

Latency <	33	13 (54.2)	12 (66.7)	8 (29.6)	0.03
7days					8
CS	25	10 (41.7)	3 (16.7)	12 (44.4)	0.13
hCAM	39	12 (54.6)	8 (50)	19 (76)	0.17
Funisitis	30	9 (40.9)	4 (25)	17 (68)	0.02

229 Data are expressed as the median (range) or n (%)

- ^a Tocolysis agents are intravenous magnesium sulfate and/or ritodrine hydrochloride
- and/or oral nifedipine.

230

- 232 b Complete protocol is defined as the cases in which all standard antibiotic regimens
- 233 (intravenous 2 g ampicillin every 6 hours for 2 days, one oral dose of 1 g azithromycin,
- and 5 days of oral 500 mg amoxicillin every 8 hours) had been completed.
- ^c The latency is defined as the period between PPROM and delivery.
- BMI, body mass index; ART, assisted reproductive technology; CHT, chronic
- 237 hypertension; DM, diabetes mellitus; HDP, hypertensive disorders of pregnancy; GDM,
- 238 gestational diabetes mellitus; GA, gestational age; PPROM, preterm premature rupture
- of membranes; CS, cesarean section; hCAM, histological chorioamnionitis
- The median gestational week at PPROM and delivery did not differ among the
- three groups. However, latency from PPROM to delivery was significantly prolonged in

the group with increased Ureaplasma after the antibiotic regimen. There was no difference in the incidence of histological chorioamnionitis (hCAM), but funisitis was significantly more common in the group with increased Ureaplasma after the antibiotic regimen (p=0.02).

Figure 2 shows the changes in vaginal Ureaplasma spp. before and after the antibiotic regimen. The median microbial load of vaginal Ureaplasma DNA at the time of PPROM was $1.9 \times 10^7 (1.8 \times 10^2 - 4.6 \times 10^9)$. Many cases had increased vaginal Ureaplasma, especially in patients who completed the antibiotic regimen. As shown in Figure 3, Lactobacillus spp. decreased after the antibiotic regimen in almost all cases. Table 2 shows the vaginal and maternal blood Ureaplasma, vaginal M. hominis,

Lactobacillus spp., and inerolysin classified by vaginal Ureaplasma changes. All M. hominis-positive cases were positive for vaginal Ureaplasma. Three patients had a positive vaginal M. hominis result at the time of PPROM and did not decrease in all cases after antibiotic regimen, but rather turned positive in three new cases. The loss of Lactobacillus spp. was more common in patients who completed the antibiotic regimen, especially in the group with increased Ureaplasma. hCAM and funisitis were more common in those with completed antibiotic regimen, regardless of vaginal Ureaplasma changes due to the antibiotic regimen and presence of Ureaplasma at the time of

PPROM (aOR,7.5; 95% CI; 2.1–26.6; P = 0.002, aOR4.5; 95%CI 1.4–11.4; P = 0.01, respectively). Among incomplete the antibiotic regimen, there were less funisitis in the group with decreased Ureaplasma due to antibiotic therapy than in the group with increased or negative Ureaplasma at the time of PPROM.

Table 2. *Ureaplasma* in vagina and maternal blood, vaginal *Mycoplasma hominis*, vaginal *Lactobacillus spp*, and inerolysin classified by whether the antibiotic regimen was completed or not and how vaginal *Ureaplasma* was changed

			complete protocol			uncomplete protocol		
			Ureaplasma	a (+) at the	Ureapl	Ureaplasn	Ureaplasma (+) at the	
			time of PPF	ROM	asma	time of PF	time of PPROM	
			increased	decreased	(-) at	increase	decreased	a (-)
			Ureaplas	Ureaplas	the	d	Ureaplasm	at the
			ma after	ma after	time of	Ureapla	a after	time
			antibiotic	antibiotic	PPRO	sma	antibiotic	of
			regimen	regimen	M	after	regimen	PPRO
						antibioti		M
						c		
						regimen		
		N	18	6	12	8	12	13
befor	vaginal	Up	15	3	_	5	10	_

e	Ureaplasm	Uu	3	2		3	3	_
antib	a						(duplicatio	
iotic							n1)	
regi		unkno	0	1	_	0	0	_
men		wn						
	vaginal <i>Urea</i>	 plasma	1.8 × 10 ⁷	6.8 × 10 ⁸	_	1.1×10^{7}	1.2 × 10 ⁸	_
	DNA (cp/mL	.)	(1.7 ×	(1.8 ×		(3.7 ×	$(6.8 \times 10^2 -$	
			10 ⁴ –2.3 ×	10 ² –4.6 ×		105-2.2	1.4×10^9)	
			108)	109)		× 10 ⁸)		
	maternal bloc	od	0	1	0	0	0	0
	Ureaplasma	(+)						
	vaginal M. ho	ominis	2 (11.1)	0	0	0	1 (8.3)	0
	(+)							
	vaginal		15 (83.3)	6 (100)	11	8 (100)	12 (100)	13
	Lactobacillus	s (+)			(91.7)			(100)
	Inerolysin (+)	9/15 (60)	3/6 (50)	6/11	4/8 (50)	10/12	3/13
	among Lactb	acillus			(54.5)		(83.3)	(23.1)
after	vaginal <i>Urea</i>	plasma	4.8 × 10 ⁷	8.0 × 10 ⁶	1.7 ×	4.1 × 10 ⁸	4.2 × 10 ⁶	_
antib			(2.8 ×	(0-7.9 ×	106	(8.7 ×	(0–7.3 ×	
iotic			10 ⁷ –6.9 ×	107)	(positi	106-3.4	108)	
regi			109)		ve	× 10 ¹⁰)		
men					conver			
					sion1)			
	maternal bloo	od	0	1 (16.7)	0	1 (12.5)	0	0
	Ureaplasma	(+)						
	vaginal M. ho	ominis	4 (22.2)	1 (16.7)	0	0	1 (8.3)	0
	(+)							
	<u> </u>		1	1	1	1	1	

	vaginal	decrea	15 (100)	6 (100)	10	8 (100)	12 (100)	11
	Lactobacill	se			(90.9)			(84.6)
	us	loss	12 (80)	4 (66.7)	5	4 (50)	4 (33.3)	2
					(45.4)			(15.4)
	Inerolysin (+)	1/6 (16.7)	0	4/6	0	1/8 (12.5)	0
	among Lactb	acillus			(66.7)			
Ureap	lasma in the pl	acenta	14 (87.5)	3 (75)	0	8 (100)	8 (72.7)	1
(unexa	amined)		(n = 2)	(n = 2)	(n = 1)		(n = 1)	(n =
								1)
hCAM	[14 (82.3)	4 (100)	9	4 (57.1)	4 (33.3)	4
(unexa	amined)		(n = 1)	(n=2)	(81.8)	(n=1)		(33.3)
					(n = 1)			(n =
								1)
Funisit	tis		12 (70.6)	3 (60)	7	4 (57.1)	1 (8.3)	2
					(63.6)			(16.7)

- 270 Data are expressed as the median (range) or n (%).
- 271 PPROM, preterm premature rupture of membranes; Up, *Ureaplasma parvum*; Uu,
- 272 Ureaplasma urealyticum; M. hominis, Mycoplasma hominis; hCAM, histological
- 273 chorioamnionitis

- Table 3 shows the neonatal complications according to vaginal *Ureaplasma*
- 276 changes. Vaginal *Ureaplasma* changes were not associated with neonatal intensive care

unit admission, neonatal sepsis, mechanical ventilation, or BPD. However, BPD was more frequent in those who completed protocol than in those who did not complete the protocol, regardless of vaginal Ureaplasma changes due to the antibiotic regimen, presence of Ureaplasma at the time of PPROM, and gestational age at delivery. (aOR, 7.2; 95%CI 1.3–40.1; P = 0.02)

Table 3. The neonatal complications according to vaginal Ureaplasma changes due to the antibiotic regimen

	Total	Ureaplasma	Ureaplasma-positive				
		- negative	decreased	increased			
			after	after			
			treatment	treatment			
	N = 69	N = 24	N = 18	N = 27			
Stillbirth	4	1 (4.2)	1 (5.6)	2 (7.4)			
neonatal death	1	0	0	1 (3.7)			
infant death	2	1	0	1 (3.7)			
delivery at other	4	1	2	1			
hospital							
infant outcome ^a	N = 60	N = 22	N = 15	N = 23	p		
birth weight(g)	2018 (520–	1957 (692–	2172 (864–	2016 (520–	0.97		
	3010)	2918)	2958)	3010)			
NICU admission	54 (90)	21 (95.5)	14 (93.3)	19 (82.6)	0.32		
male infant	37 (61.7)	15 (68.2)	10 (66.7)	12 (52.3)	0.49		
Apgar score $(5) < 7$	7 (11.7)	3 (13.6)	2 (13.3)	2 (8.7)	0.85		
pH < 7.1	0	0	0	0	-		
mechanical	27 (45)	9 (40.9)	5 (33.3)	13 (56.5)	0.33		
ventilation							
RDS	18 (30)	6 (27.3)	4 (26.7)	8 (34.8)	0.82		
ROP	13 (21.7)	5 (22.7)	3 (20)	5 (21.7)	0.98		

Data are expressed as the median (range) or n (%).

284

285

286

287

288

289

290

291

292

^aAfter excluding four cases delivered at other hospitals, four stillbirths, and one early

neonatal death, 60 cases were included in the study of infant complications.

NICU, neonatal intensive care unit; RDS, respiratory distress syndrome; ROP,

retinopathy of prematurity; IVH, intraventricular hemorrhage; PVL, periventricular

leukomalacia; NEC, necrotizing enterocolitis; BPD, bronchopulmonary dysplasia

Discussion

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

Almost all *Lactobacillus* spp. decreased or disappeared, while most vaginal Ureaplasma and M. hominis increased after the antibiotic regimen, particularly in patients who completed the regimen. Patients with increased vaginal *Ureaplasma* had longer latency. This result did not indicate that cases of increased *Ureaplasma* would have a longer latency period. Rather, the longer period reflected *Ureaplasma* that was not reduced by antibiotic therapy grew intravaginally. The longer latency from PPROM may increase the likelihood of ascending infection of *Ureaplasma* to the amnion despite the antibiotic therapy. The possibility of avoiding invasive amniocentesis was considered if *Ureaplasma* could be detected in maternal blood in the presence of intrauterine *Ureaplasma* infection. However, it was impractical because *Ureaplasma* in maternal blood was undetectable in most cases. Antibiotics were recommended for women with PPROM to prolong the delivery latency interval and reduce chorioamnionitis and neonatal sepsis. (8, 9, 17, 18) A regimen of intravenous ampicillin and erythromycin followed by oral amoxicillin and erythromycin has been commonly used. (8) Recently, azithromycin has been used instead of erythromycin because of its low cost, better side effect profile, ease of administration, and antibiotic resistance. The resistance of *Ureaplasma* and

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

Mycoplasma to erythromycin was reported to be over 80%. (19) Azithromycin was associated with a similar latency interval and lower rate of clinical chorioamnionitis for women with PPROM.(12, 20) Tanaka reported the eradication of *Ureaplasma* in the amniotic fluid of patients with PPROM treated with intravenous ampicillin–sulbactam and oral azithromycin.(21) Kacerovsky showed that intravenous clarithromycin was related to the reduced *Ureaplasma* DNA load in the amniotic fluid of patients with PPROM.(10) Conversely, Gomez reported that antibiotic administration (ceftriaxone, clindamycin, and erythromycin for 10–14 days) rarely eradicates intra-amniotic infection in patients with preterm PROM.(22) A report showed that azithromycin effectively eradicated respiratory tract *Ureaplasma* colonization in preterm infants. (23) In this study, most vaginal *Ureaplasma* was increased after the antibiotic regimen, suggesting an increasing resistance of *Ureaplasma* to azithromycin. In previous reports, the resistance rates of *U. urealyticum and M. hominis* to azithromycin also increased by about 14%–19.5%. (24, 25) In this study, there was an increased frequency of hCAM, funisitis, and BPD in cases that completed the antibiotic regimen. An increased vaginal *Ureaplasma* increased the frequency of funisitis but not the incidence of neonatal infection and BPD. These suggest that even if the antibiotic regimen contributes to a prolonged gestational

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

age, it may increase the frequency of intrauterine infection or neonatal infection from proliferated *Ureaplasma* and decreased *Lactobacillus* spp. Many studies presented that Ureaplasma was associated with adverse pregnancy outcomes and neonatal morbidities, such as preterm delivery, PPROM, chorioamnionitis, BPD,(6, 26) intraventricular hemorrhage, (27) and necrotizing enterocolitis. (28) Macrolides have anti-inflammatory properties that might reduce lung damage in preterm infants and treat bacterial infections(29); they reduce BPD in preterm infants. (30, 31) In this study, respiratory samples from infants were not obtained for *Ureaplasma* culture, so it was unknown whether the infants had *Ureaplasma* infection. The sample size was insufficient to validate the neonatal morbidity, so further research is needed. Lactobacillus, the most frequently isolated microorganism from a healthy human vagina, is touted to prevent the invasion of pathogens and ensure vaginal epithelial homeostasis. (32) The loss of *Lactobacillus* and increase in Gram-negative rods, such as Gardnerella vaginalis, lead to bacterial vaginosis. (33) In a recent study. L. crispatus, L. gasseri, L. jensenii, and L. iners, were the most frequently isolated in the vaginas of healthy childbearing age or pregnant women. (34) A vaginal microbiota that is rich in L. crispatus, L. gasseri, and L. jensenii is often associated with a lower risk of bacterial vaginosis and preterm birth. Conversely, L. iners may play a role in the

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

pathogenesis of bacterial vaginosis associated with preterm birth.(35, 36) L. iners alone detected in vaginal smears of healthy women in early pregnancy might be related to preterm delivery.(35) L. iners secretes the cholesterol-dependent cytolysins (CDC), inerolysin, as well as one of the CDC family, vaginolysin, produced by G. vaginalis. (37) In this study, about half of the cases had inerolysin, which may be related to the fact that the subjects in this study were cases of PPROM. There was no difference in the increase in vaginal *Ureaplasma* with or without inerolysin. *Lactobacillus* spp. was decreased after the antibiotics therapy regardless of the presence or absence of inerolysin. It is unclear whether *Lactobacillus* spp., reduced by antibiotic therapy, will recover spontaneously. It may be challenging to reduce *Ureaplasma* with this antibiotic therapy; we may rather focus on *Lactobacillus* formulations. The strength of this study is that it is the first to investigate both vaginal Ureaplasma and Lactobacillus changes caused by ampicillin and azithromycin regimens. This was also an examination at a single institution with a uniform management policy. However, it has several limitations. In this study, vaginal cultures were collected rather than from amniotic fluid through transabdominal amniocentesis, which does not directly indicate amniotic fluid infection. There were three reasons why the specimens were vaginal secretions. First, the purpose of this study was to observe

366

367

368

369

370

371

372

373

374

Almost all *Lactobacillus* spp. decreased while most vaginal *Ureaplasma and M.*hominis increased after the antibiotic regimen. This suggests that *Ureaplasma* and *M.*hominis became resistant to azithromycin. Future studies are needed to revalidate current antibiotic therapy for PPROM because azithromycin-resistant *Ureaplasma* and *M. hominis* are widespread in the vaginal tract.

384 Acknowledgements

We gratefully acknowledge the work of the medical staff of our center for their

assistance in specimen collection.


- 389 1. Mercer BM. Preterm premature rupture of the membranes. Obstetrics and
- 390 gynecology. 2003;101(1):178-93.
- 391 2. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of
- 392 preterm birth. Lancet (London, England). 2008;371(9606):75-84.
- 393 3. Lorthe E, Torchin H, Delorme P, Ancel PY, Marchand-Martin L, Foix-L'Hélias
- L, et al. Preterm premature rupture of membranes at 22-25 weeks' gestation: perinatal and
- 395 2-year outcomes within a national population-based study (EPIPAGE-2). American
- journal of obstetrics and gynecology. 2018;219(3):298.e1-.e14.
- 397 4. Morris JM, Roberts CL, Bowen JR, Patterson JA, Bond DM, Algert CS, et al.
- 398 Immediate delivery compared with expectant management after preterm pre-labour
- rupture of the membranes close to term (PPROMT trial): a randomised controlled trial.
- 400 Lancet (London, England). 2016;387(10017):444-52.
- 401 5. Paramel Jayaprakash T, Wagner EC, van Schalkwyk J, Albert AY, Hill JE,
- 402 Money DM. High Diversity and Variability in the Vaginal Microbiome in Women
- 403 following Preterm Premature Rupture of Membranes (PPROM): A Prospective Cohort
- 404 Study. PloS one. 2016;11(11):e0166794.
- 405 6. Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, et
- 406 al. Association between pulmonary ureaplasma colonization and bronchopulmonary
- 407 dysplasia in preterm infants: updated systematic review and meta-analysis. The Pediatric
- 408 infectious disease journal. 2014;33(7):697-702.
- 409 7. Lee J, Romero R, Kim SM, Chaemsaithong P, Yoon BH. A new antibiotic
- 410 regimen treats and prevents intra-amniotic inflammation/infection in patients with
- 411 preterm PROM. The journal of maternal-fetal & neonatal medicine : the official journal
- of the European Association of Perinatal Medicine, the Federation of Asia and Oceania
- 413 Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(17):2727-37.
- 414 8. Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD,
- et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture
- of the membranes. A randomized controlled trial. National Institute of Child Health and
- Human Development Maternal-Fetal Medicine Units Network. Jama. 1997;278(12):989-
- 418 95.
- 419 9. Mercer BM, Arheart KL. Antimicrobial therapy in expectant management of
- 420 preterm premature rupture of the membranes. Lancet (London, England).
- 421 1995;346(8985):1271-9.
- 422 10. Kacerovsky M, Romero R, Stepan M, Stranik J, Maly J, Pliskova L, et al.
- 423 Antibiotic administration reduces the rate of intraamniotic inflammation in preterm

- 425 2020;223(1):114.e1-.e20.
- 426 11. Siegler Y, Weiner Z, Solt I. ACOG Practice Bulletin No. 217: Prelabor Rupture
- of Membranes. Obstetrics and gynecology. 2020;136(5):1061.
- 428 12. Seaman RD, Kopkin RH, Turrentine MA. Erythromycin vs azithromycin for
- 429 treatment of preterm prelabor rupture of membranes: a systematic review and meta-
- analysis. American journal of obstetrics and gynecology. 2022;226(6):794-801.e1.
- 431 13. Hollander D. Diagnosis of chorioamnionitis. Clinical obstetrics and gynecology.
- 432 1986;29(4):816-25.
- 433 14. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American journal of
- respiratory and critical care medicine. 2001;163(7):1723-9.
- 435 15. Wynn JL, Wong HR, Shanley TP, Bizzarro MJ, Saiman L, Polin RA. Time for
- a neonatal-specific consensus definition for sepsis. Pediatric critical care medicine: a
- journal of the Society of Critical Care Medicine and the World Federation of Pediatric
- 438 Intensive and Critical Care Societies. 2014;15(6):523-8.
- 439 16. Byun R, Nadkarni MA, Chhour KL, Martin FE, Jacques NA, Hunter N.
- 440 Quantitative analysis of diverse Lactobacillus species present in advanced dental caries.
- Journal of clinical microbiology. 2004;42(7):3128-36.
- 442 17. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for
- preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial.
- ORACLE Collaborative Group. Lancet (London, England). 2001;357(9261):979-88.
- 445 18. Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217.
- 446 Obstetrics and gynecology. 2020;135(3):e80-e97.
- 447 19. Redelinghuys MJ, Ehlers MM, Dreyer AW, Lombaard HA, Kock MM.
- 448 Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in
- pregnant women. BMC infectious diseases. 2014;14:171.
- 450 20. Navathe R, Schoen CN, Heidari P, Bachilova S, Ward A, Tepper J, et al.
- 451 Azithromycin vs erythromycin for the management of preterm premature rupture of
- membranes. American journal of obstetrics and gynecology. 2019;221(2):144.e1-.e8.
- 453 21. Tanaka S, Tsumura K, Nakura Y, Tokuda T, Nakahashi H, Yamamoto T, et al.
- New antibiotic regimen for preterm premature rupture of membrane reduces the incidence
- of bronchopulmonary dysplasia. The journal of obstetrics and gynaecology research.
- 456 2019;45(5):967-73.
- 457 22. Gomez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, et al. Antibiotic
- 458 administration to patients with preterm premature rupture of membranes does not
- eradicate intra-amniotic infection. The journal of maternal-fetal & neonatal medicine :

- 461 Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.
- 462 2007;20(2):167-73.
- 463 23. Viscardi RM, Terrin ML, Magder LS, Davis NL, Dulkerian SJ, Waites KB, et
- al. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants. Archives
- of disease in childhood Fetal and neonatal edition. 2020;105(6):615-22.
- 24. Zhang W, Li L, Zhang X, Fang H, Chen H, Rong C. Infection Prevalence and
- 467 Antibiotic Resistance Levels in Ureaplasma urealyticum and Mycoplasma hominis in
- 468 Gynecological Outpatients of a Tertiary Hospital in China from 2015 to 2018. The
- Canadian journal of infectious diseases & medical microbiology = Journal canadien des
- 470 maladies infectieuses et de la microbiologie medicale. 2021;2021:8842267.
- 25. Zhang S, Xu K, Liu SX, Ye XL, Huang P, Jiang HJ. Retrospective Analysis of
- 472 Azithromycin-Resistant Ureaplasma urealyticum and Mycoplasma hominis Cervical
- 473 Infection Among Pregnant Women. Infection and drug resistance. 2023;16:3541-9.
- 474 26. Kotecha S, Hodge R, Schaber JA, Miralles R, Silverman M, Grant WD.
- 475 Pulmonary Ureaplasma urealyticum is associated with the development of acute lung
- 476 inflammation and chronic lung disease in preterm infants. Pediatric research.
- 477 2004;55(1):61-8.
- 478 27. Kasper DC, Mechtler TP, Böhm J, Petricevic L, Gleiss A, Spergser J, et al. In
- 479 utero exposure to Ureaplasma spp. is associated with increased rate of bronchopulmonary
- 480 dysplasia and intraventricular hemorrhage in preterm infants. Journal of perinatal
- 481 medicine. 2011;39(3):331-6.
- 482 28. Okogbule-Wonodi AC, Gross GW, Sun CC, Agthe AG, Xiao L, Waites KB, et
- al. Necrotizing enterocolitis is associated with ureaplasma colonization in preterm infants.
- 484 Pediatric research. 2011;69(5 Pt 1):442-7.
- 485 29. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease.
- 486 Pediatric pulmonology. 2001;31(6):464-73.
- 487 30. Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for
- 488 prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis.
- 489 Neonatology. 2014;106(4):337-47.
- 490 31. Razak A, Alshehri N. Azithromycin for preventing bronchopulmonary dysplasia
- 491 in preterm infants: A systematic review and meta-analysis. Pediatric pulmonology.
- 492 2021;56(5):957-66.
- 493 32. Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of
- 494 Lactobacillus derivatives in maintaining vaginal health. Microbial cell factories.
- 495 2020;19(1):203.


- 496 33. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis
- 497 is improved by a standardized method of gram stain interpretation. Journal of clinical
- 498 microbiology. 1991;29(2):297-301.
- 499 34. Kiss H, Kögler B, Petricevic L, Sauerzapf I, Klayraung S, Domig K, et al.
- Vaginal Lactobacillus microbiota of healthy women in the late first trimester of
- 501 pregnancy. BJOG: an international journal of obstetrics and gynaecology.
- 502 2007;114(11):1402-7.
- 503 35. Petricevic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Krondorfer I,
- et al. Characterisation of the vaginal Lactobacillus microbiota associated with preterm
- delivery. Scientific reports. 2014;4:5136.
- 506 36. Payne MS, Newnham JP, Doherty DA, Furfaro LL, Pendal NL, Loh DE, et al.
- A specific bacterial DNA signature in the vagina of Australian women in midpregnancy
- 508 predicts high risk of spontaneous preterm birth (the Predict1000 study). American journal
- of obstetrics and gynecology. 2021;224(2):206.e1-.e23.
- Rampersaud R, Planet PJ, Randis TM, Kulkarni R, Aguilar JL, Lehrer RI, et al.
- Inerolysin, a cholesterol-dependent cytolysin produced by Lactobacillus iners. Journal of
- 512 bacteriology. 2011;193(5):1034-41.

Figure 3 Change of microbial load of vaginal Lactobacillus spp. DNA before and after antibiotic regimen




*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours

Figure 1 Flowchart of the study population



*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours

Figure 2 Change of microbial load of vaginal *Ureaplasma* DNA before and after antibiotic regimen



*intravenous ampicillin 2 g every 6 hours for 2 days and a single oral dose of azithromycin 1 g followed by 5 days of oral amoxicillin 500 mg every 8 hours